Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Uterine Leiomyosarcoma Samples
2.2. Immunohistochemistry
2.3. Cells and Reagents
2.4. Cell Viability Assay
2.5. Measurement of Cell Cycle Phase Distribution
2.6. RNA Extraction and Gene Expression
2.7. RNA-Sequencing
2.8. Transcriptome Profiles Analysis
2.8.1. Transcriptome Data Analysis
2.8.2. Functional Enrichment Analysis
2.8.3. Key Transcription Factor Identification
2.8.4. Survival Analysis of BRD Genes Expression in Sarcoma Patients
2.9. Statistical Analysis
3. Results
3.1. The BET Proteins BRD2, BRD3, and BRD4 Are Aberrantly Overexpressed in uLMS Tissues Compared to Adjacent Myometrium from Women with uLMS
3.2. Inhibition of BET BRDs Altered uLMS Cell Viability
3.3. Inhibition of BET BRDs Induces Cell Cycle Arrest in uLMS Cells
3.4. BET Protein Inhibition Causes Transcriptome Alterations in uLMS Cells
3.5. Pathway Analysis of DEGs upon JQ1 and I-BET 762 Treatments
3.6. JQ1 and I-BET 762 Treatment Altered the Expression of Epigenetic Regulators
3.7. JQ1 and I-BET 762 Treatment Altered the Expression of m6A Regulators
3.8. The Impact of BET BRD Gene Expression on Survival Rates in Sarcoma Patients
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- D’Angelo, E.; Prat, J. Uterine sarcomas: A review. Gynecol. Oncol. 2010, 116, 131–139. [Google Scholar] [CrossRef] [PubMed]
- Yang, Q.; Madueke-Laveaux, O.S.; Cun, H.; Wlodarczyk, M.; Garcia, N.; Carvalho, K.C.; Al-Hendy, A. Comprehensive Review of Uterine Leiomyosarcoma: Pathogenesis, Diagnosis, Prognosis, and Targeted Therapy. Cells 2024, 13, 1106. [Google Scholar] [CrossRef] [PubMed]
- Seagle, B.L.; Sobecki-Rausch, J.; Strohl, A.E.; Shilpi, A.; Grace, A.; Shahabi, S. Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecol. Oncol. 2017, 145, 61–70. [Google Scholar] [CrossRef]
- Hensley, M.L.; Blessing, J.A.; Mannel, R.; Rose, P.G. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: A Gynecologic Oncology Group phase II trial. Gynecol. Oncol. 2008, 109, 329–334. [Google Scholar] [CrossRef] [PubMed]
- Yang, Q.; Bariani, M.V.; Falahati, A.; Khosh, A.; Lastra, R.R.; Siblini, H.; Boyer, T.G.; Al-Hendy, A. The Functional Role and Regulatory Mechanism of Bromodomain-Containing Protein 9 in Human Uterine Leiomyosarcoma. Cells 2022, 11, 2160. [Google Scholar] [CrossRef]
- Gadducci, A.; Landoni, F.; Sartori, E.; Zola, P.; Maggino, T.; Lissoni, A.; Bazzurini, L.; Arisio, R.; Romagnolo, C.; Cristofani, R. Uterine leiomyosarcoma: Analysis of treatment failures and survival. Gynecol. Oncol. 1996, 62, 25–32. [Google Scholar] [CrossRef]
- Zuccala, E. Epigenetics: Misdirecting methylation to drive oncogenesis. Nat. Rev. Cancer 2016, 16, 410. [Google Scholar] [CrossRef]
- Wong, C.C.; Qian, Y.; Yu, J. Interplay between epigenetics and metabolism in oncogenesis: Mechanisms and therapeutic approaches. Oncogene 2017, 36, 3359–3374. [Google Scholar] [CrossRef]
- Yang, Q.W.; Liu, S.; Tian, Y.; Salwen, H.R.; Chlenski, A.; Weinstein, J.; Cohn, S.L. Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. Cancer Res. 2003, 63, 6299–6310. [Google Scholar]
- Yang, Q.; Zage, P.; Kagan, D.; Tian, Y.; Seshadri, R.; Salwen, H.R.; Liu, S.; Chlenski, A.; Cohn, S.L. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma. Clin. Cancer Res. 2004, 10, 8493–8500. [Google Scholar] [CrossRef]
- Yang, Q.; Vafaei, S.; Falahati, A.; Khosh, A.; Bariani, M.V.; Omran, M.M.; Bai, T.; Siblini, H.; Ali, M.; He, C.; et al. Bromodomain-Containing Protein 9 Regulates Signaling Pathways and Reprograms the Epigenome in Immortalized Human Uterine Fibroid Cells. Int. J. Mol. Sci. 2024, 25, 905. [Google Scholar] [CrossRef] [PubMed]
- Dennis, C. Epigenetics and disease: Altered states. Nature 2003, 421, 686–688. [Google Scholar] [CrossRef]
- Feinberg, A.P. Phenotypic plasticity and the epigenetics of human disease. Nature 2007, 447, 433–440. [Google Scholar] [CrossRef]
- The Cancer Genome Atlas Research Network. Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas. Cell 2017, 171, 950–965.e28. [Google Scholar] [CrossRef]
- Yoshida, K.; Yokoi, A.; Kitagawa, M.; Sugiyama, M.; Yamamoto, T.; Nakayama, J.; Yoshida, H.; Kato, T.; Kajiyama, H.; Yamamoto, Y. Downregulation of miR-10b-5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing-based approach. Oncol. Rep. 2023, 49, 86. [Google Scholar] [CrossRef] [PubMed]
- de Almeida, B.C.; dos Anjos, L.G.; Uno, M.; da Cunha, I.W.; Soares, F.A.; Baiocchi, G.; Baracat, E.C.; Carvalho, K.C. Let-7 miRNA’s Expression Profile and Its Potential Prognostic Role in Uterine Leiomyosarcoma. Cells 2019, 8, 1452. [Google Scholar] [CrossRef]
- Jain, A.K.; Barton, M.C. Bromodomain Histone Readers and Cancer. J. Mol. Biol. 2017, 429, 2003–2010. [Google Scholar] [CrossRef]
- Fujisawa, T.; Filippakopoulos, P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat. Rev. Mol. Cell Biol. 2017, 18, 246–262. [Google Scholar] [CrossRef]
- Cribbs, A.P.; Filippakopoulos, P.; Philpott, M.; Wells, G.; Penn, H.; Oerum, H.; Valge-Archer, V.; Feldmann, M.; Oppermann, U. Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function. Front. Immunol. 2021, 12, 626255. [Google Scholar] [CrossRef]
- Filippakopoulos, P.; Picaud, S.; Mangos, M.; Keates, T.; Lambert, J.P.; Barsyte-Lovejoy, D.; Felletar, I.; Volkmer, R.; Müller, S.; Pawson, T.; et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 2012, 149, 214–231. [Google Scholar] [CrossRef]
- Wang, N.; Wu, R.; Tang, D.; Kang, R. The BET family in immunity and disease. Signal Transduct. Target. Ther. 2021, 6, 23. [Google Scholar] [CrossRef] [PubMed]
- Taniguchi, Y. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int. J. Mol. Sci. 2016, 17, 1849. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Z.; Ma, P.; Jing, Y.; Yan, Y.; Cai, M.C.; Zhang, M.; Zhang, S.; Peng, H.; Ji, Z.L.; Di, W.; et al. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1. Theranostics 2016, 6, 219–230. [Google Scholar] [CrossRef] [PubMed]
- Ji, Y.J.; Shao, Y.; Zhang, J.; Zhang, X.; Qiang, P. Bromodomain-containing protein 4 silencing by microRNA-765 produces anti-ovarian cancer cell activity. Aging 2021, 13, 8214–8227. [Google Scholar] [CrossRef]
- Kurimchak, A.M.; Shelton, C.; Herrera-Montávez, C.; Duncan, K.E.; Chernoff, J.; Duncan, J.S. Intrinsic Resistance to MEK Inhibition through BET Protein-Mediated Kinome Reprogramming in NF1-Deficient Ovarian Cancer. Mol. Cancer Res. 2019, 17, 1721–1734. [Google Scholar] [CrossRef] [PubMed]
- Jing, Y.; Zhang, Z.; Ma, P.; An, S.; Shen, Y.; Zhu, L.; Zhuang, G. Concomitant BET and MAPK blockade for effective treatment of ovarian cancer. Oncotarget 2016, 7, 2545–2554. [Google Scholar] [CrossRef] [PubMed]
- Drumond-Bock, A.L.; Bieniasz, M. The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis. Mol. Cancer 2021, 20, 145. [Google Scholar] [CrossRef] [PubMed]
- Maser, T.; Zagorski, J.; Kelly, S.; Ostrander, A.; Goodyke, A.; Nagulapally, A.; Bond, J.; Park, Y.; Saulnier Sholler, G. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma. Cancer Med. 2020, 9, 8144–8158. [Google Scholar] [CrossRef]
- Sun, C.; Yin, J.; Fang, Y.; Chen, J.; Jeong, K.J.; Chen, X.; Vellano, C.P.; Ju, Z.; Zhao, W.; Zhang, D.; et al. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 2018, 33, 401–416.e8. [Google Scholar] [CrossRef]
- Momeny, M.; Eyvani, H.; Barghi, F.; Ghaffari, S.H.; Javadikooshesh, S.; Hassanvand Jamadi, R.; Esmaeili, F.; Alishahi, Z.; Zaghal, A.; Bashash, D.; et al. Inhibition of bromodomain and extraterminal domain reduces growth and invasive characteristics of chemoresistant ovarian carcinoma cells. Anticancer Drugs 2018, 29, 1011–1020. [Google Scholar] [CrossRef]
- Bauer, K.; Berger, D.; Zielinski, C.C.; Valent, P.; Grunt, T.W. Hitting two oncogenic machineries in cancer cells: Cooperative effects of the multi-kinase inhibitor ponatinib and the BET bromodomain blockers JQ1 or dBET1 on human carcinoma cells. Oncotarget 2018, 9, 26491–26506. [Google Scholar] [CrossRef] [PubMed]
- Rhyasen, G.W.; Yao, Y.; Zhang, J.; Dulak, A.; Castriotta, L.; Jacques, K.; Zhao, W.; Gharahdaghi, F.; Hattersley, M.M.; Lyne, P.D.; et al. BRD4 amplification facilitates an oncogenic gene expression program in high-grade serous ovarian cancer and confers sensitivity to BET inhibitors. PLoS ONE 2018, 13, e0200826. [Google Scholar] [CrossRef] [PubMed]
- Shorstova, T.; Su, J.; Zhao, T.; Dahabieh, M.; Leibovitch, M.; De Sa Tavares Russo, M.; Avizonis, D.; Rajkumar, S.; Watson, I.R.; Del Rincón, S.V.; et al. Reprogramming of Nucleotide Metabolism Mediates Synergy between Epigenetic Therapy and MAP Kinase Inhibition. Mol. Cancer Ther. 2021, 20, 64–75. [Google Scholar] [CrossRef] [PubMed]
- Ram, S.; Vizcarra, P.; Whalen, P.; Deng, S.; Painter, C.L.; Jackson-Fisher, A.; Pirie-Shepherd, S.; Xia, X.; Powell, E.L. Pixelwise H-score: A novel digital image analysis-based metric to quantify membrane biomarker expression from immunohistochemistry images. PLoS ONE 2021, 16, e0245638. [Google Scholar] [CrossRef]
- Yang, Q.; Dahl, M.J.; Albertine, K.H.; Ramchandran, R.; Sun, M.; Raj, J.U. Role of histone deacetylases in regulation of phenotype of ovine newborn pulmonary arterial smooth muscle cells. Cell Prolif. 2013, 46, 654–664. [Google Scholar] [CrossRef]
- Bolger, A.M.; Lohse, M.; Usadel, B. Trimmomatic: A flexible trimmer for Illumina sequence data. Bioinformatics 2014, 30, 2114–2120. [Google Scholar] [CrossRef]
- Kim, D.; Paggi, J.M.; Park, C.; Bennett, C.; Salzberg, S.L. Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype. Nat. Biotechnol. 2019, 37, 907–915. [Google Scholar] [CrossRef]
- Liao, Y.; Smyth, G.K.; Shi, W. featureCounts: An efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 2014, 30, 923–930. [Google Scholar] [CrossRef]
- Harrow, J.; Frankish, A.; Gonzalez, J.M.; Tapanari, E.; Diekhans, M.; Kokocinski, F.; Aken, B.L.; Barrell, D.; Zadissa, A.; Searle, S.; et al. GENCODE: The reference human genome annotation for The ENCODE Project. Genome Res. 2012, 22, 1760–1774. [Google Scholar] [CrossRef]
- Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef]
- Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.; Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [Google Scholar] [CrossRef] [PubMed]
- Korotkevich, G.; Sukhov, V.; Budin, N.; Shpak, B.; Artyomov, M.N.; Sergushichev, A. Fast gene set enrichment analysis. BioRxiv 2021. [Google Scholar] [CrossRef]
- Kuleshov, M.V.; Jones, M.R.; Rouillard, A.D.; Fernandez, N.F.; Duan, Q.; Wang, Z.; Koplev, S.; Jenkins, S.L.; Jagodnik, K.M.; Lachmann, A.; et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016, 44, W90–W97. [Google Scholar] [CrossRef] [PubMed]
- Yu, G.; Wang, L.G.; Han, Y.; He, Q.Y. clusterProfiler: An R package for comparing biological themes among gene clusters. OMICS 2012, 16, 284–287. [Google Scholar] [CrossRef]
- Oliveira de Biagi, C.A., Jr.; Nociti, R.P.; Brotto, D.B.; Funicheli, B.O.; Cássia Ruy, P.; Bianchi Ximenez, J.P.; Alves Figueiredo, D.L.; Araújo Silva, W., Jr. CeTF: An R/Bioconductor package for transcription factor co-expression networks using regulatory impact factors (RIF) and partial correlation and information (PCIT) analysis. BMC Genom. 2021, 22, 624. [Google Scholar] [CrossRef]
- Filippakopoulos, P.; Qi, J.; Picaud, S.; Shen, Y.; Smith, W.B.; Fedorov, O.; Morse, E.M.; Keates, T.; Hickman, T.T.; Felletar, I.; et al. Selective inhibition of BET bromodomains. Nature 2010, 468, 1067–1073. [Google Scholar] [CrossRef]
- Nicodeme, E.; Jeffrey, K.L.; Schaefer, U.; Beinke, S.; Dewell, S.; Chung, C.W.; Chandwani, R.; Marazzi, I.; Wilson, P.; Coste, H.; et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010, 468, 1119–1123. [Google Scholar] [CrossRef] [PubMed]
- Ferri, E.; Petosa, C.; McKenna, C.E. Bromodomains: Structure, function and pharmacology of inhibition. Biochem. Pharmacol. 2016, 106, 1–18. [Google Scholar] [CrossRef]
- Shi, J.; Vakoc, C.R. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell 2014, 54, 728–736. [Google Scholar] [CrossRef]
- Lasman, L.; Hanna, J.H.; Novershtern, N. Role of m6A in Embryonic Stem Cell Differentiation and in Gametogenesis. Epigenomes 2020, 4, 5. [Google Scholar] [CrossRef]
- Fiorenzano, A.; Pascale, E.; Gagliardi, M.; Terreri, S.; Papa, M.; Andolfi, G.; Galasso, M.; Tagliazucchi, G.M.; Taccioli, C.; Patriarca, E.J.; et al. An Ultraconserved Element Containing lncRNA Preserves Transcriptional Dynamics and Maintains ESC Self-Renewal. Stem Cell Rep. 2018, 10, 1102–1114. [Google Scholar] [CrossRef] [PubMed]
- Fiorenzano, A.; Pascale, E.; Patriarca, E.J.; Minchiotti, G.; Fico, A. LncRNAs and PRC2: Coupled Partners in Embryonic Stem Cells. Epigenomes 2019, 3, 14. [Google Scholar] [CrossRef]
- Henssen, A.; Thor, T.; Odersky, A.; Heukamp, L.; El-Hindy, N.; Beckers, A.; Speleman, F.; Althoff, K.; Schäfers, S.; Schramm, A.; et al. BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget 2013, 4, 2080–2095. [Google Scholar] [CrossRef]
- Gilan, O.; Rioja, I.; Knezevic, K.; Bell, M.J.; Yeung, M.M.; Harker, N.R.; Lam, E.Y.N.; Chung, C.W.; Bamborough, P.; Petretich, M.; et al. Selective targeting of BD1 and BD2 of the BET proteins in cancer and immunoinflammation. Science 2020, 368, 387–394. [Google Scholar] [CrossRef] [PubMed]
- Kulikowski, E.; Rakai, B.D.; Wong, N.C.W. Inhibitors of bromodomain and extra-terminal proteins for treating multiple human diseases. Med. Res. Rev. 2021, 41, 223–245. [Google Scholar] [CrossRef] [PubMed]
- Baek, M.; Yoo, E.; Choi, H.I.; An, G.Y.; Chai, J.C.; Lee, Y.S.; Jung, K.H.; Chai, Y.G. The BET inhibitor attenuates the inflammatory response and cell migration in human microglial HMC3 cell line. Sci. Rep. 2021, 11, 8828. [Google Scholar] [CrossRef]
- Yang, Q.; Falahati, A.; Khosh, A.; Mohammed, H.; Kang, W.; Corachán, A.; Bariani, M.V.; Boyer, T.G.; Al-Hendy, A. Targeting Class I Histone Deacetylases in Human Uterine Leiomyosarcoma. Cells 2022, 11, 3801. [Google Scholar] [CrossRef]
- Shi, X.; Liu, C.; Liu, B.; Chen, J.; Wu, X.; Gong, W. JQ1: A novel potential therapeutic target. Pharmazie 2018, 73, 491–493. [Google Scholar]
- da Motta, L.L.; Ledaki, I.; Purshouse, K.; Haider, S.; De Bastiani, M.A.; Baban, D.; Morotti, M.; Steers, G.; Wigfield, S.; Bridges, E.; et al. The BET inhibitor JQ1 selectively impairs tumour response to hypoxia and downregulates CA9 and angiogenesis in triple negative breast cancer. Oncogene 2017, 36, 122–132. [Google Scholar] [CrossRef]
- Fu, L.L.; Tian, M.; Li, X.; Li, J.J.; Huang, J.; Ouyang, L.; Zhang, Y.; Liu, B. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 2015, 6, 5501–5516. [Google Scholar] [CrossRef]
- Puissant, A.; Frumm, S.M.; Alexe, G.; Bassil, C.F.; Qi, J.; Chanthery, Y.H.; Nekritz, E.A.; Zeid, R.; Gustafson, W.C.; Greninger, P.; et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013, 3, 308–323. [Google Scholar] [CrossRef]
- Anand, P.; Brown, J.D.; Lin, C.Y.; Qi, J.; Zhang, R.; Artero, P.C.; Alaiti, M.A.; Bullard, J.; Alazem, K.; Margulies, K.B.; et al. BET bromodomains mediate transcriptional pause release in heart failure. Cell 2013, 154, 569–582. [Google Scholar] [CrossRef] [PubMed]
- Matzuk, M.M.; McKeown, M.R.; Filippakopoulos, P.; Li, Q.; Ma, L.; Agno, J.E.; Lemieux, M.E.; Picaud, S.; Yu, R.N.; Qi, J.; et al. Small-molecule inhibition of BRDT for male contraception. Cell 2012, 150, 673–684. [Google Scholar] [CrossRef] [PubMed]
- Pérez-Peña, J.; Serrano-Heras, G.; Montero, J.C.; Corrales-Sánchez, V.; Pandiella, A.; Ocaña, A. In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment. Mol. Cancer Ther. 2016, 15, 1823–1833. [Google Scholar] [CrossRef]
- Nieto-Jiménez, C.; Alcaraz-Sanabria, A.; Pérez-Peña, J.; Corrales-Sánchez, V.; Serrano-Heras, G.; Galán-Moya, E.M.; Serrano-Oviedo, L.; Montero, J.C.; Burgos, M.; Llopis, J.; et al. Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors. Oncotarget 2017, 8, 19478–19490. [Google Scholar] [CrossRef]
- Chen, J.; Sun, Y.; Chi, Z. Regulation of hematopoiesis by hedgehog signaling (Review). Mol. Med. Rep. 2023, 27, 100. [Google Scholar] [CrossRef] [PubMed]
- Wu, A.; Turner, K.A.; Woolfson, A.; Jiang, X. The Hedgehog Pathway as a Therapeutic Target in Chronic Myeloid Leukemia. Pharmaceutics 2023, 15, 958. [Google Scholar] [CrossRef] [PubMed]
- Zhang, Y.; Beachy, P.A. Cellular and molecular mechanisms of Hedgehog signalling. Nat. Rev. Mol. Cell Biol. 2023, 24, 668–687. [Google Scholar] [CrossRef]
- Garcia, N.; Ulin, M.; Al-Hendy, A.; Yang, Q. The Role of Hedgehog Pathway in Female Cancers. J. Cancer Sci. Clin. Ther. 2020, 4, 487–498. [Google Scholar] [CrossRef]
- Garcia, N.; Al-Hendy, A.; Baracat, E.C.; Carvalho, K.C.; Yang, Q. Targeting Hedgehog Pathway and DNA Methyltransferases in Uterine Leiomyosarcoma Cells. Cells 2020, 10, 53. [Google Scholar] [CrossRef]
- Katoh, Y.; Katoh, M. Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9, 873–886. [Google Scholar] [CrossRef] [PubMed]
- Choi, J.; Manzano, A.; Dong, W.; Bellone, S.; Bonazzoli, E.; Zammataro, L.; Yao, X.; Deshpande, A.; Zaidi, S.; Guglielmi, A.; et al. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc. Natl. Acad. Sci. USA 2021, 118, e2025182118. [Google Scholar] [CrossRef] [PubMed]
- Chakraborty, P.; George, J.T.; Tripathi, S.; Levine, H.; Jolly, M.K. Comparative Study of Transcriptomics-Based Scoring Metrics for the Epithelial-Hybrid-Mesenchymal Spectrum. Front. Bioeng. Biotechnol. 2020, 8, 220. [Google Scholar] [CrossRef]
- Cai, L.; Hu, C.; Yu, S.; Liu, L.; Zhao, J.; Zhao, Y.; Lin, F.; Du, X.; Yu, Q.; Xiao, Q. Identification of EMT-Related Gene Signatures to Predict the Prognosis of Patients with Endometrial Cancer. Front. Genet. 2020, 11, 582274. [Google Scholar] [CrossRef]
- Gong, L.; Liu, G.; Zhu, H.; Li, C.; Li, P.; Liu, C.; Tang, H.; Wu, K.; Wu, J.; Liu, D.; et al. IL-32 induces epithelial-mesenchymal transition by triggering endoplasmic reticulum stress in A549 cells. BMC Pulm. Med. 2020, 20, 278. [Google Scholar] [CrossRef]
- Wen, S.; Hou, Y.; Fu, L.; Xi, L.; Yang, D.; Zhao, M.; Qin, Y.; Sun, K.; Teng, Y.; Liu, M. Cancer-associated fibroblast (CAF)-derived IL32 promotes breast cancer cell invasion and metastasis via integrin beta3-p38 MAPK signalling. Cancer Lett. 2019, 442, 320–332. [Google Scholar] [CrossRef]
- Park, J.S.; Choi, S.Y.; Lee, J.H.; Lee, M.; Nam, E.S.; Jeong, A.L.; Lee, S.; Han, S.; Lee, M.S.; Lim, J.S.; et al. Interleukin-32beta stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway. Cell Oncol. 2013, 36, 493–503. [Google Scholar] [CrossRef]
- Cheng, X.; Li, F.; Tao, Z. Tenascin-C promotes epithelial-to-mesenchymal transition and the mTOR signaling pathway in nasopharyngeal carcinoma. Oncol. Lett. 2021, 22, 570. [Google Scholar] [CrossRef]
- Kang, X.; Xu, E.; Wang, X.; Qian, L.; Yang, Z.; Yu, H.; Wang, C.; Ren, C.; Wang, Y.; Lu, X.; et al. Tenascin-c knockdown suppresses vasculogenic mimicry of gastric cancer by inhibiting ERK- triggered EMT. Cell Death Dis. 2021, 12, 890. [Google Scholar] [CrossRef]
- Yang, Z.; Zhang, C.; Qi, W.; Cui, C.; Cui, Y.; Xuan, Y. Tenascin-C as a prognostic determinant of colorectal cancer through induction of epithelial-to-mesenchymal transition and proliferation. Exp. Mol. Pathol. 2018, 105, 216–222. [Google Scholar] [CrossRef] [PubMed]
- Guo, J.Q.; Wang, C.D.; Tang, H.Y.; Sang, B.T.; Liu, X.; Yi, F.P.; Wu, X.M. PDGF-BB/PDGFRbeta promotes epithelial-mesenchymal transition by affecting PI3K/AKT/mTOR-driven aerobic glycolysis in Wilms’ tumor G401 cells. Cell Biol. Int. 2022, 46, 907–921. [Google Scholar] [CrossRef] [PubMed]
- Steller, E.J.; Raats, D.A.; Koster, J.; Rutten, B.; Govaert, K.M.; Emmink, B.L.; Snoeren, N.; van Hooff, S.R.; Holstege, F.C.; Maas, C.; et al. PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 2013, 15, 204–217. [Google Scholar] [CrossRef] [PubMed]
- Yin, J.; Guo, Y.; Li, Z. Platelet-derived growth factor-B signalling might promote epithelial-mesenchymal transition in gastric carcinoma cells through activation of the MAPK/ERK pathway. Contemp. Oncol. 2021, 25, 1–6. [Google Scholar] [CrossRef] [PubMed]
- Zhang, H.; Sun, J.D.; Yan, L.J.; Zhao, X.P. PDGF-D/PDGFRbeta promotes tongue squamous carcinoma cell (TSCC) progression via activating p38/AKT/ERK/EMT signal pathway. Biochem. Biophys. Res. Commun. 2016, 478, 845–851. [Google Scholar] [CrossRef]
- Dang, C.V. MYC on the path to cancer. Cell 2012, 149, 22–35. [Google Scholar] [CrossRef]
- Chen, X.; Johns, D.C.; Geiman, D.E.; Marban, E.; Dang, D.T.; Hamlin, G.; Sun, R.; Yang, V.W. Kruppel-like factor 4 (gut-enriched Kruppel-like factor) inhibits cell proliferation by blocking G1/S progression of the cell cycle. J. Biol. Chem. 2001, 276, 30423–30428. [Google Scholar] [CrossRef] [PubMed]
- Proença, C.; Freitas, M.; Ribeiro, D.; Rufino, A.T.; Fernandes, E.; Ferreira de Oliveira, J.M.P. The role of flavonoids in the regulation of epithelial-mesenchymal transition in cancer: A review on targeting signaling pathways and metastasis. Med. Res. Rev. 2023, 43, 1878–1945. [Google Scholar] [CrossRef]
- Bushweller, J.H. Targeting transcription factors in cancer—From undruggable to reality. Nat. Rev. Cancer 2019, 19, 611–624. [Google Scholar] [CrossRef]
- Liu, J.; Huang, Z.; Chen, H.N.; Qin, S.; Chen, Y.; Jiang, J.; Zhang, Z.; Luo, M.; Ye, Q.; Xie, N.; et al. ZNF37A promotes tumor metastasis through transcriptional control of THSD4/TGF-beta axis in colorectal cancer. Oncogene 2021, 40, 3394–3407. [Google Scholar] [CrossRef]
- Kwon, W.; Choi, S.K.; Kim, D.; Kim, H.G.; Park, J.K.; Han, J.E.; Cho, G.J.; Yun, S.; Yu, W.; Han, S.H.; et al. ZNF507 affects TGF-beta signaling via TGFBR1 and MAP3K8 activation in the progression of prostate cancer to an aggressive state. J. Exp. Clin. Cancer Res. 2021, 40, 291. [Google Scholar] [CrossRef]
- Li, K.; Xu, C.; Du, Y.; Junaid, M.; Kaushik, A.C.; Wei, D.Q. Comprehensive epigenetic analyses reveal master regulators driving lung metastasis of breast cancer. J. Cell. Mol. Med. 2019, 23, 5415–5431. [Google Scholar] [CrossRef] [PubMed]
- Gao, P.; He, M.; Zhang, C.; Geng, C. Integrated analysis of gene expression signatures associated with colon cancer from three datasets. Gene 2018, 654, 95–102. [Google Scholar] [CrossRef] [PubMed]
- Perumal, N.; Kanchan, R.K.; Doss, D.; Bastola, N.; Atri, P.; Chirravuri-Venkata, R.; Thapa, I.; Vengoji, R.; Maurya, S.K.; Klinkebiel, D.; et al. MiR-212-3p functions as a tumor suppressor gene in group 3 medulloblastoma via targeting nuclear factor I/B (NFIB). Acta Neuropathol. Commun. 2021, 9, 195. [Google Scholar] [CrossRef]
- Zhong, Q.H.; Zha, S.W.; Lau, A.T.Y.; Xu, Y.M. Recent knowledge of NFATc4 in oncogenesis and cancer prognosis. Cancer Cell Int. 2022, 22, 212. [Google Scholar] [CrossRef]
- Cheung, K.L.; Kim, C.; Zhou, M.M. The Functions of BET Proteins in Gene Transcription of Biology and Diseases. Front. Mol. Biosci. 2021, 8, 728777. [Google Scholar] [CrossRef]
- Zhou, S.; Zhang, S.; Wang, L.; Huang, S.; Yuan, Y.; Yang, J.; Wang, H.; Li, X.; Wang, P.; Zhou, L.; et al. BET protein inhibitor JQ1 downregulates chromatin accessibility and suppresses metastasis of gastric cancer via inactivating RUNX2/NID1 signaling. Oncogenesis 2020, 9, 33. [Google Scholar] [CrossRef]
- He, P.C.; Wei, J.; Dou, X.; Harada, B.T.; Zhang, Z.; Ge, R.; Liu, C.; Zhang, L.S.; Yu, X.; Wang, S.; et al. Exon architecture controls mRNA m6A suppression and gene expression. Science 2023, 379, 677–682. [Google Scholar] [CrossRef]
- Yang, Q.; Al-Hendy, A. The Functional Role and Regulatory Mechanism of FTO m6A RNA Demethylase in Human Uterine Leiomyosarcoma. Int. J. Mol. Sci. 2023, 24, 7957. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yang, Q.; Falahati, A.; Khosh, A.; Lastra, R.R.; Boyer, T.G.; Al-Hendy, A. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells 2024, 13, 1443. https://doi.org/10.3390/cells13171443
Yang Q, Falahati A, Khosh A, Lastra RR, Boyer TG, Al-Hendy A. Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma. Cells. 2024; 13(17):1443. https://doi.org/10.3390/cells13171443
Chicago/Turabian StyleYang, Qiwei, Ali Falahati, Azad Khosh, Ricardo R. Lastra, Thomas G. Boyer, and Ayman Al-Hendy. 2024. "Unraveling the Role of Bromodomain and Extra-Terminal Proteins in Human Uterine Leiomyosarcoma" Cells 13, no. 17: 1443. https://doi.org/10.3390/cells13171443